Bringing data to life with KOLs Who are KOLs? KOLs are key opinion leaders. They are experts in their scientific or…Prashant SharmaApril 16, 2022 Read More
The impact of key opinion leaders (KOLs) on the delivery of emerging novel treatments to lung cancer patients Lung cancer is one of the most common causes of death worldwide, accounting for 1.8m…Prashant SharmaApril 16, 2022 Read More
Repurposed drugs for COVID-19 Drug repurposing or repositioning is a promising approach for identifying new indications for approved or…Prashant SharmaApril 16, 2022 Read More
Immunostimulation – a key driver to combat coronavirus Although three human coronaviruses namely: SARS-CoV, MERS-CoV, and SARS-CoV-2 have hit mankind in last two…Prashant SharmaApril 15, 2022 Read More
Key aspects of building a predictive analytics engine Growth in technology has been attributed to the strong association between computational power and Big…Prashant SharmaApril 15, 2022 Read More
Interview with Anandbir Singh Brar, chief executive officer, Excelra  I have been involved with Excelra right from its inception in 2014 as part of…Prashant SharmaApril 15, 2022 Read More
Integrated text mining and data curation approaches for biomedical knowledgebase development The conversion of unstructured data into high-quality actionable insights based on information retrieval, data mining,…Prashant SharmaApril 15, 2022 Read More
G-protein coupled receptors: structures, research landscape and trends G protein-coupled receptors (GPCRs) have become a hot frontier in basic research of life sciences…Prashant SharmaApril 15, 2022 Read More
GOSTAR®: the largest online medicinal chemistry intelligence database In medicinal chemistry, the relationship between molecular structure of a compound and its biological activity…Prashant SharmaApril 15, 2022 Read More
GOBIOM’s biomarker database for enabling precision medicine Drug resistance and inadequate response to commonly administered drugs across different therapeutic indications poses a…Prashant SharmaApril 15, 2022 Read More